Talazoparib

Generic Name
Talazoparib
Brand Names
Talzenna
Drug Type
Small Molecule
Chemical Formula
C19H14F2N6O
CAS Number
1207456-01-6
Unique Ingredient Identifier
9QHX048FRV
Background

Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
...

Indication

Talazoparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. This indication is approved by the FDA, EMA, and Health Canada.
...

Associated Conditions
HRR gene-mutated (HRRm) metastatic castration-resistant prostate cancer (mCRPC), Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Associated Therapies
-
Clinical Trials
Related News

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

First Posted Date
2020-09-16
Last Posted Date
2024-12-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
36
Registration Number
NCT04550494
Locations
🇺🇸

University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States

🇺🇸

National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States

🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

and more 1 locations

Study of RP-3500, Camonsertib, in Advanced Solid Tumors

First Posted Date
2020-08-04
Last Posted Date
2024-06-26
Lead Sponsor
Repare Therapeutics
Target Recruit Count
285
Registration Number
NCT04497116
Locations
🇺🇸

Participating Site 1014, Chicago, Illinois, United States

🇺🇸

Participating Site 1006, Boston, Massachusetts, United States

🇺🇸

Participating Site 1001, Houston, Texas, United States

and more 10 locations

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

First Posted Date
2020-07-24
Last Posted Date
2024-07-03
Lead Sponsor
Alliance Foundation Trials, LLC.
Target Recruit Count
148
Registration Number
NCT04486352
Locations
🇺🇸

Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States

🇺🇸

Englewood Health, Englewood, New Jersey, United States

🇺🇸

Atlantic Health Systems/Morristown Medical Center, Morristown, New Jersey, United States

and more 18 locations

Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma

Phase 2
Not yet recruiting
Conditions
Advanced Malignant Pleural or Peritoneal Mesothelioma
Interventions
Drug: Talazoparib
First Posted Date
2020-07-08
Last Posted Date
2020-07-09
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
40
Registration Number
NCT04462809

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

First Posted Date
2020-04-08
Last Posted Date
2024-08-21
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
23
Registration Number
NCT04337970
Locations
🇺🇸

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

and more 4 locations

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

First Posted Date
2020-04-06
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
94
Registration Number
NCT04334941
Locations
🇺🇸

Cancer Hematology Centers - Flint, Flint, Michigan, United States

🇺🇸

Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States

🇺🇸

Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 562 locations

Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)

Phase 2
Active, not recruiting
Conditions
Metastatic Prostate Cancer
Interventions
Drug: Enzalutamide
Drug: Talazoparib
First Posted Date
2020-04-03
Last Posted Date
2024-08-26
Lead Sponsor
MedSIR
Target Recruit Count
54
Registration Number
NCT04332744
Locations
🇪🇸

Hospital Universitario Virgen de la Victoria, Málaga, Spain

🇪🇸

Instituto Valenciano de Oncología (IVO), Valencia, Spain

🇪🇸

Institut Català d'Oncologia Badalona, Badalona, Spain

and more 5 locations

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

First Posted Date
2019-12-20
Last Posted Date
2024-11-01
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
24
Registration Number
NCT04207190
Locations
🇺🇸

University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

First Posted Date
2019-12-05
Last Posted Date
2023-11-18
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
8
Registration Number
NCT04187833
Locations
🇺🇸

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

First Posted Date
2019-11-22
Last Posted Date
2024-06-04
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
47
Registration Number
NCT04173507
Locations
🇺🇸

Parkview Regional Medical Center, Fort Wayne, Indiana, United States

🇺🇸

Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States

🇺🇸

Sanford Bismarck Medical Center, Bismarck, North Dakota, United States

and more 322 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy